Astera Labs (NASDAQ:ALAB) Stock Rating Upgraded by Wall Street Zen

Key Points

• Astera Labs has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting positive sentiment from analysts regarding the company's stock performance.
• The stock price target for Astera Labs varies among analysts, with Evercore ISI setting a new target of $215, while Citigroup has raised its target to $275.
• Astera Labs reported a 149.5% year-over-year revenue increase for the last quarter, demonstrating significant growth, along with an earnings per share of $0.44, exceeding analysts' expectations.

Astera Labs (NASDAQ:ALAB - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Monday.

Several other equities research analysts also recently commented on the company. Barclays restated an "equal weight" rating and set a $155.00 price objective on shares of Astera Labs in a report on Monday, October 20th. Evercore ISI lifted their target price on Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Susquehanna lifted their target price on Astera Labs from $80.00 to $125.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Citigroup lifted their target price on Astera Labs from $160.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, September 17th. Finally, Cowen started coverage on Astera Labs in a research report on Tuesday, September 30th. They set a "hold" rating on the stock. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Astera Labs currently has an average rating of "Moderate Buy" and an average price target of $162.06.

Astera Labs Price Performance

Shares of ALAB opened at $186.68 on Monday. Astera Labs has a 1 year low of $47.13 and a 1 year high of $262.90. The company has a market capitalization of $31.03 billion, a price-to-earnings ratio of 333.36, a price-to-earnings-growth ratio of 4.66 and a beta of 1.38. The business has a 50-day moving average of $196.43 and a 200-day moving average of $136.92.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.11. The business had revenue of $191.93 million during the quarter, compared to the consensus estimate of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The firm's revenue for the quarter was up 149.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, sell-side analysts anticipate that Astera Labs will post 0.34 EPS for the current year.

Insider Activity

In other Astera Labs news, CFO Michael Truett Tate sold 18,861 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $183.51, for a total value of $3,461,182.11. Following the completion of the sale, the chief financial officer owned 259,512 shares in the company, valued at approximately $47,623,047.12. This trade represents a 6.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jitendra Mohan sold 91,441 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $183.51, for a total value of $16,780,337.91. Following the completion of the transaction, the chief executive officer directly owned 2,170,877 shares of the company's stock, valued at $398,377,638.27. This represents a 4.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,092,997 shares of company stock valued at $192,231,120. Corporate insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALAB. Oliver Lagore Vanvalin Investment Group purchased a new stake in Astera Labs during the 2nd quarter valued at $29,000. Bernard Wealth Management Corp. purchased a new stake in Astera Labs during the 2nd quarter valued at $36,000. Clearstead Trust LLC boosted its stake in Astera Labs by 46,100.0% during the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company's stock valued at $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company's stock valued at $43,000 after purchasing an additional 194 shares during the last quarter. Finally, Manchester Capital Management LLC boosted its stake in shares of Astera Labs by 141.5% in the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company's stock worth $44,000 after buying an additional 283 shares during the last quarter. Institutional investors own 60.47% of the company's stock.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.